Clinical Trials · NCT02896192
Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Rhythm Pharmaceuticals, Inc.
- Enrollment
- 15
- Start date
- Feb 2017
- Locations
- 7 sites, 7 countries
- Primary endpoint
- Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort)